Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic TNBC that expresses PD-L1

Fasching P, Huang M, Haiderali A, Pan W, Hu P, Chaudhuri M, De Tilleghem CLB, Cappoen N, O'Shaughnessy J (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Annals of Oncology Elsevier

Publisher: ELSEVIER

City/Town: AMSTERDAM

Pages Range: S192-S193

Conference Proceedings Title: ANNALS OF ONCOLOGY

DOI: 10.1016/j.annonc.2022.03.177

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD) US United States (USA) (US) Complete Health Economics Outcomes and Research Solutions (CHEORS) US United States (USA) (US) Baylor University (BU) US United States (USA) (US)

How to cite

APA:

Fasching, P., Huang, M., Haiderali, A., Pan, W., Hu, P., Chaudhuri, M.,... O'Shaughnessy, J. (2022). Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic TNBC that expresses PD-L1. In ANNALS OF ONCOLOGY (pp. S192-S193). AMSTERDAM: ELSEVIER.

MLA:

Fasching, Peter, et al. "Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic TNBC that expresses PD-L1." Proceedings of the ANNALS OF ONCOLOGY AMSTERDAM: ELSEVIER, 2022. S192-S193.

BibTeX: Download